NEIMETH INTERNATIONAL PHARMACEUTICALS : QUARTER 1 - FINANCIAL STATEMENT FOR 2022
April 29, 2022 at 05:49 pm
Share
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS
31 MARCH 2022
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2022
Contents
Page
Statement of Directors' responsibilities in relation to the financial statements
1
Statement of Compliance
2
Independent Auditor's Report
3
Statement of financial position
7
Statement of profit or loss and other comprehensive income
8
Statement of changes in equity
9
Statement of cash flows
10
Notes to the financial statements
11
Other national disclosures:
Statement of value added
48
Financial summary
49
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2022
31-Mar-22
31-Mar-21
Note
N'000
N'000
Turnover
8
985,247
1,281,576
Cost of sales
9
(559,534)
(741,208)
Gross profit / (Loss)
425,713
540,368
Other income
10
12,448
11,199
Marketing and distribution expenses
11
(296,596)
(272,117)
Administrative expenses
12
(318,876)
(226,330)
Exchange Gain
13
3,455
17,506
Operating profit
(173,856)
70,626
Finance costs
14
(35,077)
(42,316)
Loss before taxation
(208,933)
28,310
Income tax expense
28
-
-
Loss for the year from continued operation
(208,933)
28,310
Other comprehensive income
Gain on available for sale assets
-
-
Total other comprehensive income
-
-
Total comprehensive Loss
(208,933)
28,310
Basic (loss)/earnings per share
32
(11)
1.49
The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.
8
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2022
31-Mar-22
Oct'21 - Mar'22
Oct'20 - Mar'21
Note
N'000
N'000
N'000
N'000
Turnover
8
793,134
985,247
887,014
1,281,576
Cost of sales
9
(381,304)
(559,534)
(444,633)
(741,208)
Gross profit / (Loss)
411,830
425,713
442,381
540,368
Other income
10
6,467
12,448
6,110
11,199
Marketing and distribution expenses
11
(138,308)
(296,596)
(144,229)
(272,117)
Administrative expenses
12
(169,913)
(318,876)
(109,933)
(226,330)
Exchange Gain
13
11,909
3,455
19,423
17,506
Operating profit
121,985
(173,856)
213,752
70,626
Finance costs
14
(21,805)
(35,077)
(6,654)
(42,316)
Loss before taxation
100,180
(208,933)
207,098
28,310
Income tax expense
28
-
-
-
-
Loss for the year from continued operation
100,180
(208,933)
207,098
28,310
Other comprehensive income
Gain on available for sale assets
-
-
-
-
Total other comprehensive income
-
-
-
-
Total comprehensive Loss
100,180
(208,933)
207,098
28,310
Basic (loss)/earnings per share
32
5.27
(11.00)
10.90
1.49
31-Mar-21
The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.
8
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neimeth International Pharmaceuticals plc published this content on 29 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 April 2022 16:47:12 UTC.
Neimeth International Pharmaceuticals Plc is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Co-Amoxiclav, Gyno-Tiocosid, Miniplus, Neimelyn, Norduet, and Normoretic. Veterinary Products include Neimeth Piperazine, Neimycin Soluble Powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, Nimartem, and Pancemol. The Company operates in two geographic regions: Nigeria and Ghana.